Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET
May 31, 2023 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it is launching an investor communication program that will give investors the ability to...
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
May 04, 2023 16:01 ET
|
Vaxart, Inc.
On track to report key top line data from two Phase 2 norovirus vaccine studies mid-year and in Q3 2023 Continue to anticipate cash runway into Q2 2024 Conference call today at 4:30 p.m. ET SOUTH...
Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4
April 28, 2023 08:00 ET
|
Vaxart, Inc.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6
March 29, 2023 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings,...
Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
March 17, 2023 08:00 ET
|
Vaxart, Inc.
Company to provide a detailed overview of its norovirus clinical program Webcast to be held on March 28, 2023 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) --...
Vaxart Provides Business Update and Full Year 2022 Financial Results
March 15, 2023 16:01 ET
|
Vaxart, Inc.
Prioritizing oral bivalent norovirus candidate, one of the most advanced norovirus vaccines in development Will continue preclinical development of novel COVID-19 vaccine constructs to enhance...
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
March 08, 2023 16:05 ET
|
Vaxart, Inc.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate
February 14, 2023 08:00 ET
|
Vaxart, Inc.
Study to evaluate safety and immunogenicity of oral norovirus vaccine in healthy adults SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced...
Vaxart Names Phillip Lee as Chief Financial Officer
December 19, 2022 08:00 ET
|
Vaxart, Inc.
Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more than $20 billion in transactions SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Vaxart,...
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
December 01, 2022 08:00 ET
|
Vaxart, Inc.
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to...